Visualizing the cell and gene therapy supply chain of the future

In by

Spotlight Article


Dr Phil Vanek



Dr Phil Vanek is General Manager of GE Healthcare’s Cell Therapy Technologies business, a business initiative funded in part by GE Healthymagination, a $6 billion strategy to revolutionize the world’s health by improving the quality, access and affordability of care. Prior to joining GE, Phil was Head of Innovation for Lonza’s Pharmaceutical division, leading a group of research scientists, process development engineers, and commercial strategists to drive new technology initiatives focused on cell, protein, and viral therapeutic manufacturing. Phil’s career has included a number of senior innovation, business and market development roles at Becton Dickinson, Invitrogen, and Life Technologies, as well as two start-up biotechnology companies in the Washington, DC area. Phil received his Ph.D. in Biochemistry and Molecular Biology from Georgetown University Medical Center and subsequently held an IRTA fellowship at the National Cancer Institute in the Laboratory of Molecular Oncology. Phil is an active member of the Alliance for Regenerative Medicine, where he currently serves as an Officer of the Executive Committee. Phil has also been recently elected to the Centre of Commercialization of Regenerative Medicine (CCRM) Board of Directors in Toronto, Canada, and serves on the Editorial Board of Cell and Gene Therapy Insights